Site-Directed Combination Chemotherapy

  • Joseph G. Cory


In the treatment of human neoplasia, major biological problems present obstacles which make the cure of human cancer difficult. These problems center around the heterogeneous nature of a tumor cell population and the invasive and metastatic potential of this tumor cell population (1–3). The major forms of cancer treatment involve the modalities of surgery, radiation therapy and chemotherapy. In many cases, combinations of these treatment-forms are used sequentially in an attempt to deal with the problems of metastasis and heterogeneity of tumor cells. Results of current research suggest that biotherapy (use of immune regulators, differentiation inducers, etc.) may also provide an additional mode of treatment.


Adenosine Deaminase Ribonucleotide Reductase Tumor Cell Population Purine Nucleoside Phosphorylase Ribonucleotide Reductase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    I. R. Hart and I. J. Fidler, The Implications of Tumor Heterogeneity for Studies on the Biology and Therapy of C aicer Metastases, Biochim. Biophys. Acta 651: 37 (1981).PubMedCrossRefGoogle Scholar
  2. 2.
    D. L. Dexter and P. Calabresi, Intraneoplastic Diversity, Biochim. Biophys. Acta 695: 97 (1982).PubMedGoogle Scholar
  3. 3.
    G. Poste, Pathogenesis of Metastatic Disease: Implications for Current Therapy and for the Development of New Therapeutic Strategies, Cancer Treat. Rep. 70: 183 (1986).PubMedGoogle Scholar
  4. 4.
    A. C. Sartorelli and W. A. Creasey, Combination Chemotherapy, in: “Cancer Medicine,” J. F. Holland and E. Frei, III, eds., Lea and Febiger, Philadelphia (1982).Google Scholar
  5. 5.
    R. H. Blum and E. Frei, III, Combination Chemotherapy, in: “Methods in Cancer Research,” Volume XVII, V. T. DeVita, Jr., and H. Busch, eds., Academic Press, New York (1979).Google Scholar
  6. 6.
    R. E. Wittes and A. Goldin, Unresolved Issues in Combination Chemotherapy, Cancer Treat. Rep. 70: 105 (1986).PubMedGoogle Scholar
  7. 7.
    G. A. Curt, N. J. Clendeninn, and B. A. Chabner, Drug Resistance in Cancer, Cancer Treat. Rep. 68: 87 (1984).PubMedGoogle Scholar
  8. 8.
    E. Frei, III, Curative Cancer Chemotherapy, Cancer Res. 45: 6523 (1985).PubMedGoogle Scholar
  9. 9.
    J. G. Cory and A. Sato, Regulation of Ribonucleotide Reductase Activity in Mammalian Cells, Mol. Cell. Biochem. 53 /54: 257 (1983).PubMedGoogle Scholar
  10. 10.
    J. G. Cory, Role of Ribonucleotide Reductase in Cell Division, Pharmac. Therap. 21: 265 (1983).CrossRefGoogle Scholar
  11. 11.
    J. G. Cory, A. E. Fleischer, and J. B. Munro, III, Reconstitution of the Ribonucleotide Reductase Enzyme from Ehrlich Tumor Cells, J. Biol. Chem. 253: 2898 (1978).PubMedGoogle Scholar
  12. 12.
    J. G. Cory and A. E. Fleischer, Noncoordinate Changes in the Components of Ribonucleotide Reductase in Mammalian Cells, J. Biol. Chem. 257: 1263 (1982).PubMedGoogle Scholar
  13. 13.
    J. G. Cory and A. E. Fleischer, Specific Inhibitors Directed at the Individual Components of Ribonucleotide Reductase as an Approach to Combination Chemotherapy, Cancer Res. 39: 4600 (1979).PubMedGoogle Scholar
  14. 14.
    J. G. Cory, A. Sato, and L. Lasater, Specific Inhibition of the Subunits of Ribonucleotide Reductase as a New Approach to Combination Chemotherapy, Adv. Enz. Reg. 19: 139 (1981).CrossRefGoogle Scholar
  15. 15.
    R. C. Jackson, The Regulation of Thymidylate Biosynthesis in Novikoff Hepatoma Cells and the Effects of Amethopterin, 5-Fluorodeoxyuridine, and 3-Deazauridine, J. Biol. Chem. 253: 7440 (1978).PubMedGoogle Scholar
  16. 16.
    J. G. Cory, D. A. Rey, G. L. Carter, and P. E. Bacon, Nucleoside 5’-Diphosphates as Effectors of Mammalian Ribonucleotide Reductase, J. Biol. Chem. 260: 1201 (1985).Google Scholar
  17. 17.
    R. C. Jackson, A Kinetic Model of Regulation of the Deoxyribonucleoside Triphosphate Pool Composition, Pharmac. Therap. 24: 279 (1984).CrossRefGoogle Scholar
  18. 18.
    J. G. Cory and G. L. Carter, Drug Action on Ribonucleotide Reductase, Adv. Enz. Reg. 24: 385 (1986).CrossRefGoogle Scholar
  19. 19.
    J. A. Montgomery, The Biological Bases for the Design of Anticancer Agents, in: “Cancer Biology and Therapeutics,” J. G. Cory and A. Szentivanyi, eds., Plenum Press, New York (1986).Google Scholar
  20. 20.
    H. L. Elford, B. Van’t Riet, G. L. Wampler, A. L. Lin, and R. M. Elford, Regulation of Ribonucleotide Reductase in Mammalian Cells by Chemotherapeutic Agents, Adv. Enz. Reg. 19: 151 (1981).CrossRefGoogle Scholar
  21. 21.
    J. G. Cory, G. L. Carter, P. E. Bacon, A. T’ang, and E. J. Lien, Inhibition of Ribonucleotide Reductase and L1210 Cell Growth by NHydroxy-N’-Aminoguanidine Derivatives, Biochem. Pharm. 34: 2645 (1985).PubMedCrossRefGoogle Scholar
  22. 22.
    A. C. Sartorelli, K. C. Agarwal, and E. C. Moore, Mechanism of Inhibition of Ribonucleotide Diphosphate Reductase by a-(N)-Heterocyclic Aldehyde Thiosemicarbazones, Biochem. Pharm. 20: 3119 (1971).PubMedCrossRefGoogle Scholar
  23. 23.
    J. G. Cory, A. Sato, P. E. Bacon, and D. A. Rey, Nucleoside 5’-Triphosphate Analogs as Positive and Negative Inhibitors of Mammalian Ribonucleotide Reductase, Cancer Biochem. Biophys. 8: 23 (1985).PubMedGoogle Scholar
  24. 2.4.
    J. G. Cory, L. Lasater, and A. Sato, Effects of Iron-Chelating Agents on Inhibitors of Ribonucleotide Reductase, Biochem. Pharm. 30: 979 (1984).CrossRefGoogle Scholar
  25. 25.
    A. Sato, J. A. Montgomery, and J. G. Cory, Synergistic Inhibition of Leukemia L1210 Cell Growth In Vitro by Combinations of 2-Fluoroadenine Nucleosides and Hydroxyurea or 2,3-Dihydro-1 H-pyrazole [2,3-a] imidazole, Cancer Res. 44: 3286 (1984).PubMedGoogle Scholar
  26. 26.
    H. J. Schaeffer and C. F. Schwender, Bridging Hydrophobic and Hydrophilic Regions of Adenosine Deaminase with Some 9-(2-hydroxy-3alkyl) Adenines, J. Med. Chem. 17: 6 (1974).PubMedCrossRefGoogle Scholar
  27. 27.
    J. A. Montgomery, The Chemistry and Biology of Nucleosides of Purines and Ring Analogs, in: “Proceedings of the Fifth International Roundtable on Nucleosides, Nucleotides, and their Biological Applications,” Academic Press, New York (1983).Google Scholar
  28. 28.
    J. D. Stoeckler, C. Canbor, V. Kuhns, S-H. Chu, and R. E. Parks, Jr., Inhibitors of Purine Nucleoside Phosphorylase C(8) and C(5’) Substitutions, Biochem. Pharm. 31: 163 (1982).PubMedCrossRefGoogle Scholar
  29. 29.
    I. S. Kazmers, B. S. Mitchell, P. E. Dadonna, L. L. Wotring, L. B. Townsend, and W. B. Kelley, Inhibition of Purine Nucleoside Phosphorylase by 8-Aminoguanosine: Selective Toxicity for T-Lymphoblasts, Science 214: 1137 (1981).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Joseph G. Cory
    • 1
  1. 1.Department of BiochemistryUniversity of South Florida College of MedicineTampaUSA

Personalised recommendations